N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models ; volume:9 ; number:1 ; day:4 ; month:10 ; year:2017 ; pages:1-12 ; date:12.2017
Alzheimer's research & therapy ; 9, Heft 1 (4.10.2017), 1-12, 12.2017

Classification: Medizin, Gesundheit

Creator: Wirths, Oliver

Contributor: Walter, Susanne
Kraus, Inga
Klafki, Hans W.
Stazi, Martina
Oberstein, Timo J.
Ghiso, Jorge
Wiltfang, Jens
Bayer, Thomas A.
Weggen, Sascha
SpringerLink (Online service)

DOI: 10.1186/s13195-017-0309-z

URN: urn:nbn:de:1111-2017112812437

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wirths, Oliver
Walter, Susanne
Kraus, Inga
Klafki, Hans W.
Stazi, Martina
Oberstein, Timo J.
Ghiso, Jorge
Wiltfang, Jens
Bayer, Thomas A.
Weggen, Sascha
SpringerLink (Online service)

Other Objects (12)

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

Related objects

Reset password